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Summary Characterisation of altered glycosylation of P-glycoprotein (P-gp) found associated with the
absence of a multidrug resistance (MDR) phenotype in cell lines prompted an investigation to assess the role
of post-translational processing in establishing P-gp efflux pump functionality. The clone A cell line used in
this study displays a strong MDR phenotype mediated by high constitutive levels of expression of P-gp.
Incubation of clone A cells with tunicamycin for different periods resulted in a time-dependent increase in
daunorubicin accumulation, reflecting a reduction in P-gp function. Parallel experiments conducted with
verapamil resulted in no loss of P-gp functionality in clone A cells. Reduction in surface-associated P-gp
following exposure to tunicamycin was established by FACS analysis, Western blot analysis and
immunoprecipitation of surface-iodinated P-gp. In addition, immunoprecipitation of P-gp from 32p_
orthophosphate-labelled cells demonstrated reduced phosphorylation of P-gp associated with tunicamycin
exposure. From these studies we conclude that glycosylation of P-gp is required to establish the cellular MDR
phenotype.
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Various steps in the biosynthesis of P-glycoprotein (P-gp)
were characterised in a number of previous studies and dem-
onstrated that P-gp is synthesised as a 140kDa precursor,
processed via N-linked glycosylation to a mature 170kDa
transmembrane glycoprotein (Greenberger et al., 1988;
Richert et al., 1988; Loo and Clarke, 1994). A second step in
the biosynthesis involves phosphorylation of the mature
170kDa glycoprotein (Richert et al., 1988), which is con-
sidered to be an essential event in establishing a fully func-
tional efflux pump (Hamada et al., 1987; Bates et al., 1992;
Kramer et al., 1993a,b). Since the 140 kDa precursor
molecule is not phosphorylated in the resting state (Kramer
et al., 1993a) and the mature 170 kDa protein is localised in
the membrane, it is likely that phosphorylation is mediated
by kinases acting at the plasma membrane (Staats et al.,
1990). Modulation of the phosphorylation and functional
status of P-gp by the tumour promoter phorbol ester 4p-
phorbol 12p myristate 13az-acetate suggests that protein
kinase C (PKC) may be one kinase mediating this event
(Hamada et al., 1987; Chambers et al., 1990, 1992). In addi-
tion, P-gp has been shown to be an in vitro substrate for
protein kinase A (PKA) (Mellado and Horowitz, 1987), and
both PKC and PKA phosphorylation domains have been
identified (Orr et al., 1993). Although the phosphorylation
status of P-gp has been shown to be strongly correlated with
the MDR phenotype in cell lines (Kramer et al., 1993a),
there is little direct evidence demonstrating a requirement for
phosphorylation in establishing functionality. However, a
recent study by Bates et al. (1992) has demonstrated an
association between decreased P-gp phosphorylation and in-
creased drug accumulation in a human colon cell line
exposed to sodium butyrate. Moreover, antisense DNA
directed against PKC3 a has been shown to decrease the drug
resistance of MCF-7/Adr cells (Ahmed and Glazer, 1993).
In contrast, glycosylation events associated with matura-
tion of the 140 kDa precursor molecule are not considered
important in establishing the functionality of the P-gp efflux
pump (Chou and Kessel, 1981; Beck and Cirtain, 1982). Two
lines of evidence suggest this to be the case. First, exposure
of a drug-resistant cell line, CEM/VLB100, to pronase or
tunicamycin does not diminish the activity of drug efflux in
these cells (Beck and Cirtain, 1982). Second, colchicine-
resistant hamster cell mutants displaying an altered car-
bohydrate moiety of P-gp retain a competent MDR
phenotype in drug uptake assays (Ling et al., 1983). Our
previous studies, using a panel of human colon carcinoma
cell lines, have identified two P-gp mutants in which altered
processing of similar levels of the immature P-gp results in
markedly different MDR phenotypes (Kramer et al., 1993a).
Underglycosylation of the immature 140 kDa P-gp in the
Moser cell line results in an aberrant, mature 160 kDa pro-
tein which is phosphorylated, cell surface associated and
capable ofconferring the full MDR phenotype on these cells,
confirming observations from earlier studies (Ling et al.,
1983). Cell line DLD-1 synthesises similar levels of immature
140 kDa precursor to Moser but displays little mature pro-
tein, minimal phosphorylation and greatly reduced cell-
surface detectable P-gp. In contrast to the Moser cell line,
DLD-1 is characterised by the absence of an MDR pheno-
type (Kramer et al., 1993a). These findings raise questions as
to the role of glycosylation in establishing a functional P-gp
efflux pump. In this study we report the requirement for
glycosylation of P-gp to establish a competent cellular MDR
phenotype.
Materials and methods
Cell lines and drug exposure
Human colorectal carcinoma cell lines were maintained in
culture in Dulbecco's modified Eagle medium (DMEM) sup-
plemented with 5% fetal calf serum. Cell lines clone A and
DLD-1 were provided by Dr D Dexter (DuPont De
Nemours, Wilmington, DE, USA). Cell line MIPIOI was
established by Dr Niles (West Virginia, USA). The Moser
cell line was kindly provided by Dr M Brattain (Medical
College of Ohio, Toledo, OH, USA). The remaining cell lines
were obtained from the American Type Culture Collection
(ATCC). The P-gp status of the aforementioned cell lines has
been previously established by this group (Kramer et al.,
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November 19941993a). Tunicamycin was added to complete medium at a
final concentration of 2.5p,gmlm' (3pM). Verapamil was
used at a final concentration of 4 gmlml (10pM).
Immunoprecipitation ofP-gp andepidermalgrowthfactor
receptor (EGFR)
Subconfluent dishes of cell lines were washed twice in
phosphate-buffered saline (PBS) and incubated for 1 h in
methionine-free or phosphate-free DMEM followed by
incubation in [35S]methionine (150l.Ci ml-') or [32P]ortho-
phosphate (150ftCiml-') respectively. In pulse chase experi-
ments cells were labelled for 10 min and chased in complete
DMEM for different periods. In all other experiments label-
ling was for 3 h followed by immunoprecipitation of P-gp
using the same protocol. Metabolically labelled cells were
rinsed briefly in phosphate-buffered saline (PBS) and lysed in
PBSTDS buffer (PBS pH 7.4, 1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulphate, 2mM
phenylmethylsulphonylfluoride, 10 Uml-' aprotinin). Lysis
was carried out for 20 min at 4°C, followed by shearing of
lysates through a 24 gauge needle. Lysates were clarified in a
microfuge for 20 min at 4°C, supernatants were removed and
10jl aliquots were taken for protein estimation using the
bovine serum albumin (BSA) protein assay system (Pierce,
Rockford, IL, USA). Before immunoprecipitation samples
were standardised for protein concentration. Overnight
incubation of lysates at 4°C with MDR-1 polyclonal
antibody (Oncogene Science, Uniondale, NY, USA) was fol-
lowed by a 90 min incubation with protein A-Sepharose
beads. Immune complexes were washed three times in PBS
then incubated in standard sample buffer for 20 min at room
temperature. All samples were run on 7.5% polyacrylamide
gels, dried and exposed for 1-3 days on X-ray film.
Functional assays
P-gp activity was determined using a daunorubicin accumula-
tion assay (Kramer et al., 1993a). Replicate suspensions of
colon cells (2 x 106 cellsml-') were incubated at 37°C for
90 min in medium containing daunorubicin (3 tiM) in the
presence or absence of verapamil or tunicamycin. In a
separate experiment, cells were exposed to tunicamycin
(2.5 lgml-') or verapamil (4Itgml-') for 24-36 h, washed
twice in PBS and then assayed for daunorubicin accumula-
tion, as described above. Cellular daunorubicin fluorescence
was quantitated by flow cytometric analysis using Becton-
Dickinson (Mountain View, CA, USA) FACSort and
LYSYS II software.
Flow cytometry
Surface staining of cells for P-gp expression was accomp-
lished using the 4E3 anti-Pg-p monoclonal antibody (MAb)
(Arceci et al., 1993). Adherent cells were collected in cold
PBS by gentle scraping with a rubber policeman. Cells were
washed twice in cold PBS and 1 x 106 cells were resuspended
in 100 JLl of PBS containing a 1:1 dilution of human serum
with PBS and incubated at 4°C for 30min to block Fc
receptors. Then, 2 ml of PBS was added to the cells, which
were collected by centrifugation at 600g for 3 min. Pelleted
cells were resuspended in 100yl of PBS containing 2% goat
serum and 10 igmlhl anti-P-gp MAb 4E3 or an IgG2a
isotype-matched control antibody. This mixture was in-
cubated for 30 min at 4°C. Cells were then washed twice with
cold PBS and then resuspended in 100jil of PBS containing
2% goat serum and fluorescein isothiocyanate (FITC)-
labelled goat anti-mouse Ig (Fab)2 fragment (TAGO) at a
1:30 dilution. Cells were incubated with the second antibody
for 30 min at 4°C in the dark, then washed twice in cold PBS
and fixed in 2% paraformaldehyde before analysis. The level
of P-gp expression was determined using a Becton-Dickinson
FACSscan II and LYSYS software application.
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125Isurface labelling ofcells
All procedures were carried out on ice. Cells to be labelled
(5 x 106) were suspended in 1 ml of PBS and then added to
0.5 mCi of neutralised Na'25I in 0.1 ml of PBS and lac-
toperoxidase (40yg in water, 1 mgml-). To start the
reaction, 10ftl of hydrogen peroxide [30% (v/v) hydrogen
peroxide in 10 ml of PBS] was added and mixed gently for
10 min. An additional 10fil of hydrogen peroxide was added
after this period followed by a final 10 ilI of hydrogen perox-
ide 10 min later. Finally, 10 ml of PBS was added to the
reaction mixture and the cells were pelleted by centrifugation.
Cells were washed five times with 10ml volumes of PBS,
lysed in PBSTDS, clarified in a microfuge and precipitated
overnight with MDR-1 antibody from 400 tLg of total protein
per sample (Kramer et al., 1993b).
Western blot analysis
Crude membrane extracts were prepared from washed (PBS)
pelleted cells harvested from dishes by scraping. Cells were
exposed to hypotonic solution (10 mM Tris pH 7.2, 10mM
sodium chloride, 1.5 mM magnesium chloride, 1 mM dithio-
threitol, 2mM phenylmethylsulphonyl fluoride, 10Uml-'
aprotinin), vortexed and clarified in a microfuge (4000g) for
5 min at 4°C. The supernatant was removed and the pellet
resuspended in 1 ml of hypotonic solution, followed by
incubation at 4°C for 15 min. The mixture was further dis-
rupted in a Dounce homogeniser (60 strokes) and centrifuged
at 7500 r.p.m. for 10 min at 4°C. The supernatants were
removed and spun in an ultracentrifuge for 1 h (40000g) at
4°C. Pellets were resuspended in PBSTDS lysis buffer and
protein concentrations were determined for each preparation.
Total protein-standardised samples were immunoprecipitated
using MDR-1 polyclonal antibody (Oncogene Science,
Uniondale, NY, USA), resolved in 7.5% polyacrylamide gels
and transferred overnight to nitrocellulose membrane. Blots
were probed with MAb C219 (2jgml-') as recommended by
the manufacturer (Centocor, Malvern, PA, USA) and
developed using the ECL Western blotting detection system
(Amersham, Aylesbury, UK).
Results
Effect oftunicamycin on P-gp synthesis
To investigate the hypothesis that glycosylation of P-gp is
required for the acquisition of the MDR phenotype in cells,
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Figure 1 Biosynthesis ofP-gp in the human colon carcinoma cell
line clone A. Pulse labelling of cells was performed in the
presence of [35S]methionine for a period of 10 min. Labelled cells
were washed briefly and incubated in methionine-supplemented
medium for different chase periods. Cells were then lysed and
P-gp was immunoprecipitated as described in the Materials and
methods section. Immunoprecipitated protein was separated on a
7.5% resolving gel, dried and exposed to X-ray film from
between 1 and 3 days. The 140 kDa precursor (0) and 170 kDa
mature P-gp (D>) can be resolved. Numbered lanes represent
different chase periods, lane 1, 0 h; lane 2, 2 h; lane 3, 4 h; lane 4,
6h; lane 5, 8h; lane 6, lOh.Glycosylation events in P-gp functionality
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we repeated and extended the experiments of Beck and Cir-
tain (1982) using the MDR-competent colon carcinoma cell
line clone A. Pulse-chase labelling experiments demonstrated
P-gp synthesised as a 140 kDa precursor molecule in clone A,
which is converted to the mature 170 kDa glycoprotein over
a 4-6 h period (Figure 1), consistent with results reported by
other groups (Richert et al., 1988). Figure 2 shows
immunoprecipitation of P-gp from clone A cells exposed to
tunicamycin (2.5 Lg ml-') demonstrating synthesis of precur-
sor throughout continued exposure to the glycosylation
inhibitor. Resolution of the 140 kDa precursor and 170 kDa
mature P-gp was observed in the absence of tunicamycin
(Figure 2, lane 1) and when label and drug were added
together (Figure 2, lane 2). However, 6 h exposure to
tunicamycin was sufficient to block completely glycosylation
of newly synthesised P-gp (Figure 2, lane 3) resulting in an
unglycosylated precursor molecule which migrates more
rapidly than the previously characterised 140 kDa precursor
(Figure 2, compare lower band in lanes 2 and 3). The migra-
tional difference observed in repeated experiments is sugges-
tive of some co-translation glycosylation events associated
with the P-gp precursor product.
Functional assessment oftunicamycin on the MDR phenotype
If glycosylation of P-gp is required for establishing the MDR
phenotype, continuous maintenance of clone A cells in the
presence of tunicamycin should compromise the functionality
of the efflux pump. Figure 3 shows results from a study in
which the zero time point demonstrates that the P-gp
antagonist verapamil was able to increase the accumulation
of daunorubicin by a factor of 4 when co-administered with
daunorubicin, thus confirming the functional activity of P-gp
in these cells. However, daunorubicin accumulation was not
affected by co-administering tunicamycin over a range of
doses in excess of those that block P-gp glycosylation,
demonstrating that tunicamycin is not a MDR inhibitor in
this system (Figure 3). These results contrast with those seen
after exposing cells to verapamil or tunicamycin for 24 or
36 h (Figure 3) when cells were washed free of drug before
conducting the daunorubicin accumulation assay. Under
these conditions, verapamil had no effect on daunorubicin
accumulation, whereas tunicamycin treatment resulted in a
time-dependent increase in daunorubicin accumulation, re-
flecting a loss in P-gp function. These values were established
over three separate experiments and represent a 5- to 7-fold
reduction in pump efficacy compared with that recorded in
untreated or in chronic verapamil-treated, clone A cells.
Surface expression ofP-gp
Acquisition of the cellular MDR phenotype is likely to be
dependent upon localisation of P-gp in the plasma mem-
brane. To establish whether the compromised MDR pheno-
type observed in tunicamycin-treated clone A cells results
from a reduction in surface-associated P-gp we used MAb
4E3 in FACS analysis on live cells. This antibody recognises
an external epitope of human MDR-1 P-gp, independent of
the glycosylation status of this molecule (Arceci et al., 1993;
Schinkel et al., 1993a). Using this approach on clone A cells
incubated in the presence of tunicamycin for 24 (Figure 4b),
36 (Figure 4c) and 48 (Figure 4d) h, revealed a reduction in
surface-associated P-gp. Figure 4 shows approximately a 1.6-
fold reduction in detectable cell-surface P-gp following 48 h
exposure to tunicamycin.
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Figure 3 Functional assessment of P-gp activity in the presence
of tunicamycin. P-gp activity was determined using a dauno-
rubicin accumulation assay. Cells were maintained in the presence
of verapamil ( M , 4 lAgml-', 10jAM) or tunicamycin ( 1,
2.5jgml-', 3fsM) for 0, 24 or 36h. Cells were then washed free
of drug and replicate suspensions (2 x 106 cellsml-') were
incubated at 37C for 90 min in medium containing daunorubicin
(3 JiM). Untreated control values ( = ) at 24 and 36 h were
within 10% of the time zero control values. Cellular dauno-
rubicin fluorescence was quantitated by flow cytometric analysis.
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Figure 2 Effect of tunicamycin on the biosynthesis of P-gp.
Colon cell line, clone A, was incubated in the presence of
tunicamycin (2.5fjgml-') for different periods. Metabolic label-
ling of cells with [35S]methionine was performed during the last
3 h of drug exposure. Cells were lysed and P-gp was immuno-
precipitated as described in the Materials and methods section.
The numbered lanes represent different periods of exposure to
tunicamycin. Lane 1, 0 h; lane 2, 3 h; lane 3, 6 h; lane 4, 12 h;
lane 5, 18h; lane 6, 24h; lane 7, 36h.
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Figure 4 MDR-1 P-gp surface expression decreases with
tunicamycin exposure. Clone A cells were stained with either the
4E3 MAb or an IgG2a isotype control following different time
periods in the presence of tunicamycin as described in the
Materials and methods section. (a) Clone A stained with IgG2a
control (black histogram) vs 4E3 staining (white histogram).
Black histograms in b, c and d represent the untreated clone A
cells stained with 4E3 as a baseline comparison for 4E3 staining
(white histograms) following different exposure times to tunica-
mycin: (a) Oh; (b) 24 h; (c) 36 h; (d) 48 h.
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Membrane-associated expression ofP-gp
To characterise the level of expression and species, i.e.
glycosylated or unglycosylated, of P-gp in the plasma mem-
brane of tunicamycin-treated clone A cells, we prepared
plasma membrane isolates of cells and probed protein-
standardised immunoprecipitated lysates with MAb C219 in
Western blot analysis. Figure 5 shows a representative experi-
ment in which the 170 kDa mature P-gp is found in un-
treated clone A cells (Figure 5, lane 3) with a corresponding
reduction in this glycoprotein in membrane preparations
from clone A cells exposed to tunicamycin for different
periods (Figure 5, lanes 4-6). In repeated experiments a
second band, migrating with the unglycosylated precursor
molecule, was faintly detected. To establish the possibility of
the presence of membrane-associated precursor P-gp in
200 1
170 1
Figure 5 Western blot analysis of membrane-associated P-gp
following exposure of clone A cells to tunicamycin. Crude mem-
brane extracts were prepared from cell lines as outlined in the
Materials and methods section. Total protein-standardised sam-
ples were immunoprecipitated using MDR-1 polyclonal antibody,
resolved in 7.5% gels and transferred overnight to nitrocellulose
membrane. Blots were probed with MAb C219 and developed
using the ECL Western blot detection system. Lane 1, MIP-1OI,
high-level expressor of membrane P-gp; lane 2, CCL 228, low-
level expressor ofmembrane P-gp; lanes 3-6 represent membrane
extracts from clone A cells exposed to tunicamycin for different
periods. Lane 3, 0 h; lane 4, 12h; lane 5, 24 h; lane 6, 36 h.
Unmarked left lane shows 200 kDa molecular weight marker.
tunicamycin-treated cells, we performed surface iodination of
live cells followed by immunoprecipitation of P-gp from
protein-standardised cell lysates. Figure 6 shows detection of
only the mature (170 kDa) P-gp in untreated clone A cells
(Figure 6, lane 3) with a reduction in the P-gp associated
with exposure to tunicamycin (Figure 6, lanes 4 and 5),
consistent with results of Western blot analysis. It is clear
from these experiments that the unglycosylated P-gp
(140kDa) is iodinated in live cells and precipitated by the
MDR-1 antibody in repeated assays.
Phosphorylation status ofP-gp
Our previous studies of colon carcinoma cell lines revealed
phosphorylation associated solely with the mature 170 kDa
P-gp, in which the phosphorylation level showed a strong
correlation with the MDR phenotype of the cells (Kramer et
al., 1993a). Immunoprecipitation of P-gp from cells labelled
for 3 h with [32P]orthophosphate revealed high levels ofphos-
phorylation associated with the 170 kDa P-gp in untreated
clone A cells (Figure 7, lane 1), consistent with our previous
findings. In contrast, cells exposed to tunicamycin for
extended periods displayed a significant reduction in phos-
phorylation associated with the mature P-gp (170kDa)
(Figure 7, lanes 2-4) with evidence ofphosphorylation ofthe
unglycosylated 140 kDa precursor molecule. The cell lines
HT29 (Figure 7, lane 5) and MIPIOI (Figure 7, lane 6)
represent negative and positive P-gp controls respectively.
Discussion
In this study we have evaluated the role of glycosylation of
P-gp in establishing the cellular MDR phenotype. These
studies were prompted by the identification of two P-gp
mutants in a panel of human colon carcinoma cell lines
which displayed altered processing of P-gp, resulting in con-
trasting MDR phenotypes (Kramer et al., 1993a). Both cell
lines were established before chemotherapy and have not
subsequently been exposed to known chemotherapeutic
agents, hence representing constitutive expression of P-gp.
The Moser cell line has previously been reported to syn-
thesise a 140 kDa P-gp precursor molecule which displays an
aberrant carbohydrate moiety (Kramer et al., 1993a) similar
to that reported for P-gp in drug-selected Chinese hamster
ovary cell lines (Ling et al., 1983). As with the hamster cell
lines, the Moser line displays a competent MDR phenotype
in which the altered mature P-gp is both membrane
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Figure 6 Immunoprecipitation of P-gp from surface-iodinated
colon carcinoma cells. Surface iodination of cells was performed
as described in the Materials and methods section, followed by
lysis and immunoprecipitation of P-gp using MDR-1 polyclonal
antibody. Lane 1, MIP-101, high-level expressor of membrane
P-gp; lane 2, CCL 228, low-level expressor of membrane P-gp;
lane 3, clone A; lane 4, clone A exposed to tunicamycin for 12 h;
lane 5, clone A exposed to tunicamycin for 24 h. Migration of the
precursor (140 kDa) and mature (170kDa) P-gp is denoted by
arrows.
Figure 7 Phosphorylation status ofP-gp in tunicamycin-exposed
cells. Cells were incubated in the presence of [32P]orthophosphate
for 3 h followed by immunoprecipitation of P-gp as described in
the Materials and methods section. Lanes 1-4 represent clone A
cells incubated in the presence of tunicamycin (2.5 lgml-) for
different periods. Lane 1, 0 h; lane 2, 12 h; lane 3, 24 h; lane 4,
36 h, lane 5, HT29 negative control; lane 6, MIPIOI positive
control. Migration of the precursor (140 kDa) and mature
(170 kDa) P-gp is denoted by arrows.
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associated and phosphorylated, two features considered
essential components of a completely functional cellular
efflux pump. In contrast, DLD-1 synthesised similar levels of
140 kDa P-gp precursor to MDR-competent colon cell lines,
e.g. clone A and Moser, and yet displayed little or no MDR
phenotype in drug uptake assays (Kramer et al., 1993a).
Consistent with the idea that the 170 kDa P-gp is the phos-
phorylated membrane-associated species and is responsible
for the MDR phenotype, DLD-1 has been shown to have
greatly reduced surface-localised P-gp and minimal func-
tionality in drug uptake assays (Kramer et al., 1993a). These
observations suggest that glycosylation of the precursor P-gp
is important in establishing a competent MDR phenotype in
these cells.
To address this issue in more detail, we have repeated and
extended studies initially performed by Beck and Cirtain
(1982), using the colon carcinoma cell line clone A, which
has been shown to constitutively express P-gp and display a
competent MDR phenotype (Kramer et al., 1993a). In con-
trast to previous studies in which drug-resistant cells exposed
to tunicamycin for 48 h maintained a competent MDR
phenotype (Chou and Kessel, 1981; Beck and Cirtain, 1982),
we found increased drug retention in clone A cells exposed to
tunicamycin suggestive of a role for glycosylation in estab-
lishing the P-gp-mediated MDR phenotype. Following
exposure of clone A cells to tunicamycin (2.5#igml-') for
36 h, retention of daunorubicin was 5- to 7-fold greater than
that recorded in clone A cells exposed to verapamil
(4 igml-') for the same period or in untreated clone A cells.
Interestingly, FACS analysis of tunicamycin-exposed clone A
cells, using MAb 4E3, revealed only a 1.6-fold reduction in
cell-surface-associated P-gp following 48 h of tunicamycin
exposure, although surface iodination and Western blot
analysis suggest more significant reductions in membrane-
associated P-gp. With the demonstrated effective inhibition of
glycosylation by tunicamycin on newly synthesised P-gp, why
is the MDR phenotype not completely abrogated? Given that
the viability of cells exposed to tunicamycin drops rapidly
after 48 h and that the half-life of P-gp is between 48 and
72 h (Richert et al., 1988), it is clear that a significant propor-
tion of presynthesised P-gp will remain throughout the time
course of experiments in this study. Hence, with this
approach one would not expect to abolish the P-gp-mediated
MDR phenotype within the time frame of these studies.
Given this limitation, one explanation for the discrepancy
between our results and those of Beck and Cirtain (1982)
could relate to the level of expression of P-gp in the cell lines
used. The cell line CEM/VLB100 was selected for resistance
to vinblastine and expresses high levels of P-gp. Although we
have no directly comparable data with clone A, it is likely
that the level of P-gp expression in CEM/VLB100 is greater
than recorded in clone A, as is the case with other drug-
selected cell lines (Arceci et al., 1993). In such circumstances
the elevated levels ofP-gp together with the extended half-life
of the protein combine to maintain sufficient P-gp in the
presence of tunicamycin to cope with drug efflux at the
concentrations used in drug uptake assays. Hence, only cell
lines expressing lower levels of P-gp would exhibit a compro-
mised MDR phenotype in the prsence of tunicamycin.
However, should tunicamycin exposure result in premature
degradation of newly synthesised P-gp, then reduced overall
levels of P-gp could account for the loss of MDR phenotype.
Previous studies involving the characterisation of P-gp
glycosylation mutants demonstrated that altered glycosyla-
tion of P-gp can occur without compromising the MDR
phenotype (Ling et al., 1983). We have found this to be true
in the Moser cell line, in which the altered carbohydrate
moiety of the mature P-gp does not prevent membrane
localisation and phosphorylation of P-gp resulting in a full
MDR phenotype. Whether the unglycosylated 140 kDa P-gp
precursor can maintain the MDR phenotype in vivo is
unclear, although it has been shown that a functional pump
can be established in yeast in the absence of glycosylation
(Kuchler and Thorner, 1992). Iodination studies of clone A
cells exposed to tunicamycin suggest that some unglyco-
sylated P-gp is localised at the cell surface under these condi-
tions. Since phosphorylation is considered to be an integral
component in the functionality of P-gp, it is interesting to
note that phosphorylation of a 140 kDa protein is also
detected in tunicamycin-exposed clone A cells. We have never
observed this in any case ofconstitutive expression ofP-gp in
an extended series ofcell lines studied (Kramer et al., 1993a).
Although it is evident that tunicamycin, resulting in the
inhibition of glycosylation, can affect the efficacy of the
P-gp-mediated efflux pump, it is likely that this is as a
consequence of a combination of factors. These include loss
of cell-surface-associated P-gp and reduced phosphorylation
of persisting P-gp in cells. Although unglycosylated P-gp may
prove functional in extracellular assays, the perturbation of
translocation to the membrane will compromise its efficacy as
a cellular detoxification pathway. These results are consistent
with a recent report involving mutation of the conserved
N-glycosylation sites of the human P-gp, the findings of
which suggest that glycosylation contributes to proper
routing or stability ofP-gp (Schinkel et al., 1993b). In this way
glycosylation does not contribute to functional aspects of the
P-gp pump per se but is required in establishing competent
cellular MDR phenotypes.
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